News Novo's diabetes pill beats injections in head-to-head trials Novo Nordisk is making the case for its diabetes pill, which it hopes will allow it to fight off competition from rivals in a highly competitive market.
News Regeneron's three-monthly gMG drug Livsayis cleared by FDA Regeneron has joined the crowded gMG market with an siRNA-based therapy, Livsayis, that only needs to be dosed four times a year.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.